London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Use of water-soluble tomato concentrate in preparation of composition for treating cerebral ischemia-reperfusion injury
https://patents.google.com/patent/CN116688025A/en?q=(%22water-soluble+tomato%22)&oq=%22water-soluble+tomato%22&sort=new
"Based on this, the application provides a new use of a water-soluble tomato concentrate, relating to the use of a water-soluble tomato concentrate in the preparation of a composition for preventing, alleviating or treating cerebral ischemia-reperfusion injury."
"Abstract
The present application relates to the use of a water-soluble tomato concentrate for the preparation of a composition for the treatment of cerebral ischemia-reperfusion injury. Through long-term research, researchers of the application firstly find and prove that the water-soluble tomato concentrate has obvious repairing effect on ischemic cerebral apoplexy reperfusion injury according to nerve function evaluation, tetrazolium red staining and HE staining, can obviously reduce cerebral infarction area, reduce nerve function score and improve brain tissue pathology, and can be applied to preparing a composition for treating cerebral ischemia-reperfusion injury."
:-)
"Specifically, the oral or injectable administration forms of the above composition for treating cerebral ischemia-reperfusion injury include solutions, powders, tablets, granules, capsules, emulsions and suspensions. It will be appreciated that the above-described compositions for treating cerebral ischemia-reperfusion injury may be administered by subcutaneous injection, intra-cerebral administration, intravenous injection, oral administration, or the like."
"In a specific example, the dosage of the water-soluble tomato concentrate in the composition for treating cerebral ischemia-reperfusion injury is 15mg/kg to 150mg/kg. Alternatively, the dose of water-soluble tomato concentrate in the composition for treating cerebral ischemia-reperfusion injury is 47.25mg/kg. It will be appreciated that the specific concentration may be adjusted as desired depending on the condition or individual situation."
Gixer great find , reading through that it implies the dosage should be upto 150mg per Kg of weight so a 80kg man would need a lot of ff for the dosage to work
Sounds like a great candidate for a drug !
It does. 👍
It would be great news if this was a precursor to an entry into the "Drugs Market".
However, I am slightly concerned that it is BH who have applied for a patent, rather than Provexis. Who would benefit from such a patent, if granted? Any thoughts?
Slam it makes little difference who has applied for patent as By health can only buy ff from pxs , so the more they need the more bottom line for pxs .
"thoughts"
Yes it would be good if Provexis had applied for this patent but By-Health have put in the work and paid for it. Provexis cant patent FF for every scenario.
"Who would benefit"
Well you can only assume By-Health for holding the patent and Provexis for supplying the FF.
One of my long held thoughts is that the short to medium term value of the provexis stock lies in the underlying asset of the patents held by the Company. As time goes on the number of worldwide patents has increased and has started to cover an increasing number of uses. Furthermore, the recent "Clinical Trials" performed by BH, would appear to be positive and will only add to the value of the previous trials required to gain the original EFSA approval.
In my very simplistic mind, I have ascribed an approximate value to these patents/IP of £40-50M. The current market value of the Company is £14.5M and so, I believe that there is significant hope of short to medium growth in the share price.
The share price has been held back because of the lack of a positive marketing plan for the original product and the threat of a funding shortfall.
However there are now a number of issues on the horizon that could breakthrough the negativity:
1) The possibility that provexis could move into profitability in the next 12 months
2) The grant of Blue Cap Status for the use of Fruitflow in the Chinese Market. Not only would this increase the value of the IP but it would also open up a massive new market for the product.
3) We now have two more potential uses for the product: Gut health (being investigated via DSM and; Possible drug claims under the new BH patent.
I continue to keep my fingers crossed that I am right with these thoughts, but it has been a very long time coming.
It's a good Conclusion to the Patent application.
In conclusion, under the experimental condition, the water-soluble tomato concentrate has remarkable repairing effect on rat MCAO/R injury, can remarkably reduce cerebral infarction area, reduce nerve function score, improve brain tissue pathology and increase cerebral blood flow on the side of ischemia.
This is a medical intervention treatment. A drug.
It's very interesting that massive doses have a direct influence on sufferers of this horrendous condition.
I hope that the human trials can follow and that a life enhancing benefit can be added to the growing list.
Obviously, that would bring a financial gain, but I'm more excited over the possibility of such a breakthrough medically.
I didn’t know exactly what this relates to so I looked it up . Very interesting!..........Ischemia-reperfusion injury is a common feature of ischemic stroke, which occurs when blood supply is restored after a period of ischemia. Reperfusion can be achieved either by thrombolysis using thrombolytic reagents such as tissue plasminogen activator (tPA), or through mechanical removal of thrombi. Spontaneous reperfusion also occurs after ischemic stroke.
Yep. Just about the worst thing that can happen to a human short of the obvious.
I really hope that this is as significant as it appears.
I think its another great and significant bit of news on the benefits of Fruitflow.
Roll on the human trials. Although these could take a long time.
Roll on human trials. I been in this since 2009. So I can wait.
1) The possibility that provexis could move into profitability in the next 12 months
So where will the sales come from in the next 12 months ? BH will not have FF on the shelves within a year imo. Like Gixer says Human trials can take ages. PXS needs a lot of luck if you ask me, maybe a big celeb will mention it , that sort of thing.
Always ready to misread posts to create a neverhopeful slant.
ByHealth have submitted for BlueCap registration based on the health claim that has almost 15years of EFSA approval, with full human trials. IF approved, they should be able to launch immediately, given their huge spend to date.
The human trials gixer mentioned are for yet another novel health claim.
But then you knew that.
Yes alfista, from the recent RNS we all know that......
"On 29 August 2023 it was announced in China that BYHEALTH had submitted: i) the first application under the Implementation Rules, seeking to obtain a new permitted health function claim for foods such as Fruitflow which help to 'maintain normal platelet aggregation function and benefit blood flow health'; and ii) some related product registration applications."
How many products they have registered (for Blue Cap) remains an unknown but I am sure B-H will require a sizable amount of FF for any product(s) launch.
We should move into small profit without China.
1) Jan 23 - increase in profit share (step 1) and removal of DSM overheads charges.
2) Jan 23 onwards - direct customers (we hope)
3) Jan 24 - increase profit share (step 2/4)
I would think BH must have an order in now they have submitted their application to Samr . From the update in April . The Company will be in a better position to judge how best to manage its future inventory requirements (which can be met from either: (i) DSM's existing Fruitflow inventory; or (ii) a new Fruitflow production run) in the coming weeks once it has a clearer picture of: (i) the likely demand from the Company's actual and prospective Fruitflow customers for the next 12 months and beyond, to include By-Health
Don't forget By-Health is also a distributor for Fruitflow and might have already been selling it to other businesses.